The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

Astellas is preparing a significant shake-up of its top-tier roles, including transforming its chief medical officer into a new R&D position and ushering out its current chief scientific officer ...

Astellas is to work with UK biotech Adaptimmune ... and chimeric antigen receptors (CARs), important building blocks for cell therapies.. Based in Oxfordshire, Adaptimmune also has human leukocyte ...

The company said in its third-quarter results call that it is already building commercial manufacturing capacity for zolbetuximab as it anticipates the readout of the two phase 3 trials. Astellas ...

TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective ...

DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation ...

Cell and gene therapies are also a key part of Astellas’s growth strategy, building off of its 2020 acquisition of gene therapy developer Audentes Therapeutics. Within gene therapy, the Tokyo ...